Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | MAP2 | P11137 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 10/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026726 | 0.81 | PDE5A (0.38) | POLB | |
| SCHEMBL30026837 | 0.81 | TRPA1 (0.45) | SCN9ATRPA1 | |
| SCHEMBL28517414 | 0.80 | MAP2 (0.40) | SCN9AMAP2RORCTRPA1GRIA1 | |
| SCHEMBL30025942 | 0.80 | BRD4 (0.38) | — | |
| SCHEMBL30026160 | 0.79 | BRD4 (0.37) | POLB | |
| SCHEMBL30025849 | 0.78 | QPCT (0.43) | SCN9AMAP2TRPA1GRIA1CACNG8 | |
| SCHEMBL28517848 | 0.76 | RHEB (0.53) | SCN9AMAP2RORCTRPA1GRIA1 | |
| SCHEMBL30116414 | 0.76 | RHEB (0.53) | SCN9AMAP2RORCTRPA1GRIA1 | |
| SCHEMBL25719933 | 0.74 | RORC (0.43) | RORCPOLBNPSR1 | |
| SCHEMBL25719185 | 0.70 | RORC (0.40) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512055-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical uses thereof | RORC, RORB, RORA | SCN9A 1601/4885MAP2 3360/4885RORC 1/4885 |
| US-12187684-B2 | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof | RORC, RORB, RORA | SCN9A 1510/4885MAP2 3287/4885RORC 1/4885 |
| US-20230130361-A1 | Benzimidazole Derivatives as Modulators of Retinoid-Related Orphan Receptor Gamma (RORy) and Pharmaceutical Use Thereof | RORB, RORA, RORC | SCN9A 1577/4885MAP2 2625/4885RORC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.